摘要分子靶向治疗药物包括抗肿瘤血管生成剂、生长因子受体抑制剂、Scr酪氨酸激酶抑制剂、重组分子N-901、抗细胞凋亡因子Bcl-2抑制剂、Hh信号通路抑制剂等.其中抗肿瘤血管生成剂如贝伐单抗和沙力度胺均进行了大量的Ⅱ、Ⅲ试验研究用以评估其在治疗小细胞肺癌(SCLC)方面的疗效及毒性;Scr酪氨酸激酶抑制剂正在进行Ⅰ、Ⅱ期的临床试验,结果 尚未得出;重组分子N-901也正在进行一项针对广泛期SCLC的Ⅱ期的临床试验,另外Bcl-2及Hh信号通路抑制剂正在进行初期的临床试验.初步的研究数据表明SCLC对于靶向治疗不敏感,其原因有待于进一步研究.

abstractsMolecular targeted agents for small cell lung cancer have been introduced in great many clinical trials in recent years. The classes of targeted agents include antiangiogenic agents,growth factor receptor inhibitors,Bcl-2 inhibitors,SCR kinase inb.ibitors, recombinant molecules N-901 and inhibitors of the sonic hedgehog signaling pathway. The class of antiangiogenic agents,including bevacizumab and thalidomide,is be-ing evaluated in phase Ⅱ and Ⅲ trials. The tyrosine and Scr kinase inhibitors are being evaluated in phase Ⅰ and Ⅱ trials. The recombinant molecule, N-901 is undergoing phase Ⅱ testing in patients with relapsed small cell lung cancer. The other pathways undergoing evaluation for the development of pharmacologic agents include inhibiturs of bcl-2 and sonic hedgehog signaling,which are being tested in the earliest phases of clinical evalua-tion. Primary data shows small cell lung cancer is not sensitive to targeted therapy and further studies are re-quested.